ONCO.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 06:59):

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally...

Stats
Today's Volume	647 684
Average Volume	804 092
Market Cap	600.94M
EPS	SEK0 ( 2024-05-03 )
Next earnings date	( SEK0 ) 2024-05-30
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.470
ATR14	SEK0.0270 (0.93%)

Volume Correlation

Long: -0.11 (neutral)

Short: 0.45 (neutral)

Signal:(35.458) Neutral

Oncopeptides AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncopeptides AB (publ) Correlation - Currency/Commodity

-0.11
( neutral )

-0.02
( neutral )

0.00
( neutral )

0.21
( neutral )

-0.56
( weak negative )

0.66
( moderate )

Oncopeptides AB (publ) Financials

Annual	2023
Revenue:	SEK35.22M
Gross Profit:	SEK36.30M (103.06 %)
EPS:	SEK-1.960

FY	2023
Revenue:	SEK35.22M
Gross Profit:	SEK36.30M (103.06 %)
EPS:	SEK-1.960

FY	2022
Revenue:	SEK8.36M
Gross Profit:	SEK8.35M (99.93 %)
EPS:	SEK-4.11

FY	2021
Revenue:	SEK118.30M
Gross Profit:	SEK65.17M (55.09 %)
EPS:	SEK-19.00

Financial Reports:

No articles found.

Oncopeptides AB (publ)

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.